Tc99m-sestamibi uptake in osteitis fibrosa cystica simulating metastatic bone disease.
Rubin
M R
MR
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA.
Livolsi
V A
VA
Bandeira
F
F
Caldas
G
G
Bilezikian
J P
JP
D000328:Adult; D019386:Alendronate / Q000627:therapeutic use; D015415:Biomarkers; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D003937:Diagnosis, Differential; D020249:Hormone Replacement Therapy; D006801:Humans; D008297:Male; D010002:Osteitis Fibrosa Cystica / Q000000981:diagnostic imaging* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000627:therapeutic use; D010282:Parathyroid Neoplasms / Q000473:pathology / Q000601:surgery; D016105:Parathyroidectomy; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D017256:Technetium Tc 99m Sestamibi / Q000493:pharmacokinetics
D015415:Biomarkers; D010281:Parathyroid Hormone; D019275:Radiopharmaceuticals; D017256:Technetium Tc 99m Sestamibi; D019386:Alendronate